Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Working Capital Changes (2020 - 2025)

Tarsus Pharmaceuticals has reported Other Working Capital Changes over the past 6 years, most recently at -$8.2 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$8.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$1.7 million (down 636.48% YoY), and the annual figure for FY2025 was -$1.7 million, down 636.48%.
  • Other Working Capital Changes for Q4 2025 was -$8.2 million at Tarsus Pharmaceuticals, down from -$8.0 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for TARS hit a ceiling of $23.2 million in Q2 2025 and a floor of -$8.7 million in Q1 2025.
  • Median Other Working Capital Changes over the past 5 years was -$28000.0 (2022), compared with a mean of $11157.9.
  • Peak annual rise in Other Working Capital Changes hit 1548.38% in 2025, while the deepest fall reached 3660.78% in 2025.
  • Tarsus Pharmaceuticals' Other Working Capital Changes stood at $1.4 million in 2021, then tumbled by 64.93% to $484000.0 in 2022, then crashed by 60.95% to $189000.0 in 2023, then soared by 746.03% to $1.6 million in 2024, then plummeted by 612.01% to -$8.2 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$8.2 million (Q4 2025), -$8.0 million (Q3 2025), and $23.2 million (Q2 2025) per Business Quant data.